Tg Therapeutics (TGTX) Cash & Equivalents (2011 - 2026)

Tg Therapeutics' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 97.84% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 97.84% YoY), while the FY2025 annual figure was $1.3 million, up 256.6% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $2.9 million, up from $1.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $195.8 million in Q3 2024, with the low at $371000.0 in Q4 2024.
• The 5-year median for Cash & Equivalents is $102.3 million (2022), against an average of $102.7 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 99.6% in 2024, then jumped 256.6% in 2025.
• Tg Therapeutics' Cash & Equivalents stood at $102.3 million in 2022, then decreased by 9.16% to $92.9 million in 2023, then sank by 99.6% to $371000.0 in 2024, then surged by 256.6% to $1.3 million in 2025, then jumped by 116.02% to $2.9 million in 2026.
• Business Quant data shows TGTX's Cash & Equivalents at $2.9 million in Q1 2026, $1.3 million in Q4 2025, and $178.3 million in Q3 2025.